Dr. Wonkyung Byon, Former Pfizer Executive, Joins Advenchen Biosciences as Senior Vice President of A2PG
Amador Bioscience, a global leader in translational science and clinical pharmacology CRO services, announced that Dr. Wonkyung Byon has joined its clinical pharmacology brand, A2PG, as Senior Vice President, reporting to Dr. Sunny Chapel, CSO of Amador Bioscience and CEO of A2PG.
Dr. Wonkyung Byon
Prior to joining Amador Bioscience, Dr. Byon spent fifteen years at Pfizer in the United States, where she served as Senior Director of Quantitative Pharmacology and Head of the Inflammation and Immunology Team. With deep expertise in clinical pharmacology and quantitative pharmacology across multiple therapeutic areas, Dr. Byon published a seminal paper in 2013 as the first author on best practices and guidance for establishing population modeling. This publication now serves as a key reference for the development of relevant guidelines by the U.S. FDA and China’s Center for Drug Evaluation (CDE).
Dr. Byon earned her Bachelor of Pharmacy and Master of Clinical Pharmacy degrees from Seoul National University in South Korea, and received her Ph.D. in Experimental and Clinical Pharmacology from the University of Minnesota in the United States in 2007. To date, Dr. Byon has published nearly 30 papers and chaired multiple international conferences on quantitative pharmacology. She was also invited to teach the course “Model-Informed Drug Development” at the College of Pharmacy, University of Florida.
“Dr. Byon is not only an outstanding expert in clinical pharmacology and quantitative pharmacology, but also an excellent industry leader who has been committed to promoting the development of the clinical pharmacology field for many years,” said Dr. Sunny Chapel, CSO of AMADOR BIOSCIENCE and CEO of A2PG. “I am very pleased that Dr. Byon has decided to join the company. She will lead our global team to continue advancing to higher levels.”
“I am delighted to join the AMADOR BIOSCIENCE/A2PG team,” said Dr. Wonkyung Byon. “My primary career objective is to advance the innovative pharmaceutical industry toward model-informed drug development, thereby providing better treatment options for patients. I believe that AMADOR A2PG is the ideal platform to achieve this goal, and I am thrilled to join and lead a forward-thinking and creative clinical pharmacology team.”
Regarding the appointment of Dr. Byon, Dr. Wang Bing, Chairman and Chief Executive Officer of AMADOR BIOSCIENCE, stated: “I am confident that with Dr. Byon’s extensive expertise, industry experience, and strong reputation in the global community, her arrival will further solidify AMADOR BIOSCIENCE’s global leadership in clinical pharmacology, strengthen talent development within the industry, and support the development of innovative drugs worldwide.”
AMADOR BIOSCIENCE drives new drug development with clinical pharmacology as the core, providing end-to-end clinical development services that meet international standards. This includes strategic planning and execution from preclinical stages through to market approval, scientifically optimizing dose selection, target identification, and patient stratification, while adhering to global quality standards to enhance the success rate of new drug R&D. The company has established operational facilities in China, the United States, and Europe, serving a diverse clientele ranging from leading biotech startups to multinational pharmaceutical companies. To date, the AMADOR team has successfully completed over 210 marketing authorization submissions (NDA, BLA, MAA) in Europe and the United States for domestic and international clients.
A2PG is the clinical pharmacology brand under Amador Bioscience, specializing in clinical pharmacology consulting, preclinical and clinical data analysis and reporting, modeling and simulation, global regulatory support, data management, and quantitative pharmacology training. It implements model-based strategies to support key decision-making in clinical research.